Christopher Gignoux
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 52 | 2026 | 1452 | 3.470 |
Why?
| | Genetics, Population | 34 | 2026 | 215 | 3.410 |
Why?
| | Polymorphism, Single Nucleotide | 63 | 2026 | 2177 | 2.410 |
Why?
| | Genomics | 22 | 2026 | 831 | 2.020 |
Why?
| | Genome, Human | 25 | 2025 | 429 | 1.870 |
Why?
| | Genetic Predisposition to Disease | 33 | 2026 | 2417 | 1.870 |
Why?
| | Multifactorial Inheritance | 17 | 2026 | 210 | 1.770 |
Why?
| | Genetic Variation | 18 | 2025 | 1008 | 1.650 |
Why?
| | Models, Genetic | 14 | 2026 | 593 | 1.400 |
Why?
| | Asthma | 20 | 2025 | 1918 | 1.100 |
Why?
| | Transcriptome | 8 | 2026 | 1029 | 1.060 |
Why?
| | Precision Medicine | 4 | 2024 | 444 | 0.920 |
Why?
| | Haplotypes | 23 | 2025 | 496 | 0.920 |
Why?
| | Genetics, Medical | 5 | 2023 | 25 | 0.880 |
Why?
| | Biological Specimen Banks | 6 | 2026 | 99 | 0.810 |
Why?
| | Pharmacogenetics | 2 | 2021 | 167 | 0.760 |
Why?
| | Gastritis | 1 | 2023 | 115 | 0.720 |
Why?
| | Enteritis | 1 | 2023 | 104 | 0.710 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.670 |
Why?
| | Humans | 142 | 2026 | 143560 | 0.660 |
Why?
| | Human Migration | 6 | 2021 | 25 | 0.620 |
Why?
| | Gene Flow | 8 | 2020 | 85 | 0.590 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.580 |
Why?
| | Smad2 Protein | 1 | 2018 | 38 | 0.570 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 331 | 0.570 |
Why?
| | Genotype | 24 | 2025 | 1877 | 0.560 |
Why?
| | Gene Frequency | 13 | 2025 | 492 | 0.560 |
Why?
| | Pedigree | 4 | 2025 | 513 | 0.530 |
Why?
| | Thyroid Neoplasms | 3 | 2026 | 337 | 0.510 |
Why?
| | Phenotype | 16 | 2026 | 3211 | 0.500 |
Why?
| | Chromosome Mapping | 11 | 2023 | 517 | 0.470 |
Why?
| | DNA Methylation | 5 | 2025 | 667 | 0.450 |
Why?
| | Population | 2 | 2014 | 32 | 0.450 |
Why?
| | Population Growth | 2 | 2012 | 11 | 0.440 |
Why?
| | DNA, Mitochondrial | 6 | 2016 | 211 | 0.440 |
Why?
| | Metagenomics | 4 | 2023 | 180 | 0.430 |
Why?
| | Obesity | 5 | 2025 | 3041 | 0.410 |
Why?
| | Indians, North American | 7 | 2021 | 661 | 0.410 |
Why?
| | Receptors, KIR | 5 | 2022 | 110 | 0.400 |
Why?
| | Mexican Americans | 7 | 2023 | 114 | 0.400 |
Why?
| | Evolution, Molecular | 6 | 2021 | 507 | 0.390 |
Why?
| | Agriculture | 2 | 2011 | 104 | 0.390 |
Why?
| | Quantitative Trait Loci | 7 | 2025 | 368 | 0.380 |
Why?
| | Genetic Loci | 7 | 2019 | 279 | 0.360 |
Why?
| | Exome | 5 | 2022 | 240 | 0.350 |
Why?
| | Female | 58 | 2026 | 77251 | 0.350 |
Why?
| | Software | 3 | 2026 | 687 | 0.340 |
Why?
| | Molecular Epidemiology | 3 | 2023 | 72 | 0.330 |
Why?
| | Alleles | 12 | 2025 | 893 | 0.330 |
Why?
| | Indians, South American | 2 | 2020 | 23 | 0.330 |
Why?
| | Nasal Mucosa | 2 | 2025 | 111 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2026 | 406 | 0.320 |
Why?
| | Genetic Association Studies | 3 | 2022 | 377 | 0.310 |
Why?
| | Male | 55 | 2026 | 71500 | 0.310 |
Why?
| | Population Groups | 2 | 2020 | 58 | 0.300 |
Why?
| | Computational Biology | 3 | 2023 | 677 | 0.300 |
Why?
| | Linkage Disequilibrium | 9 | 2023 | 254 | 0.290 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 686 | 0.290 |
Why?
| | Gene Expression Profiling | 5 | 2025 | 1794 | 0.280 |
Why?
| | Proteome | 2 | 2024 | 494 | 0.280 |
Why?
| | Kidney Diseases | 2 | 2025 | 412 | 0.280 |
Why?
| | Skin Pigmentation | 2 | 2018 | 48 | 0.280 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2113 | 0.270 |
Why?
| | Risk Factors | 19 | 2025 | 10644 | 0.270 |
Why?
| | Selection, Genetic | 4 | 2019 | 266 | 0.260 |
Why?
| | Receptors, KIR2DL1 | 2 | 2018 | 21 | 0.260 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 191 | 0.250 |
Why?
| | Genetic Markers | 7 | 2023 | 345 | 0.250 |
Why?
| | Case-Control Studies | 12 | 2025 | 3625 | 0.250 |
Why?
| | Colorectal Neoplasms | 2 | 2025 | 833 | 0.250 |
Why?
| | Mexico | 8 | 2023 | 230 | 0.250 |
Why?
| | Data Compression | 1 | 2026 | 6 | 0.240 |
Why?
| | Phylogeography | 5 | 2020 | 58 | 0.240 |
Why?
| | Environmental Exposure | 3 | 2017 | 588 | 0.240 |
Why?
| | Body Mass Index | 5 | 2025 | 2429 | 0.240 |
Why?
| | Colorado | 4 | 2024 | 4658 | 0.240 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.240 |
Why?
| | Thyroid Diseases | 1 | 2026 | 45 | 0.230 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 17 | 0.230 |
Why?
| | Minority Groups | 2 | 2019 | 279 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2575 | 0.230 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 38 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2023 | 954 | 0.230 |
Why?
| | Aged | 17 | 2026 | 25322 | 0.220 |
Why?
| | Algorithms | 4 | 2025 | 1813 | 0.220 |
Why?
| | Puerto Rico | 8 | 2021 | 54 | 0.220 |
Why?
| | Phylogeny | 7 | 2022 | 1008 | 0.210 |
Why?
| | Bivalvia | 1 | 2024 | 7 | 0.210 |
Why?
| | Computer Simulation | 7 | 2026 | 1028 | 0.210 |
Why?
| | Killer Cells, Natural | 4 | 2021 | 475 | 0.210 |
Why?
| | Heterozygote | 3 | 2021 | 311 | 0.210 |
Why?
| | Chromosomes, Human, Pair 6 | 3 | 2014 | 47 | 0.210 |
Why?
| | Genes, MHC Class I | 2 | 2021 | 36 | 0.210 |
Why?
| | Longevity | 1 | 2025 | 175 | 0.210 |
Why?
| | Triglycerides | 3 | 2025 | 517 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 56 | 0.200 |
Why?
| | Long QT Syndrome | 1 | 2024 | 69 | 0.200 |
Why?
| | United Kingdom | 4 | 2026 | 334 | 0.200 |
Why?
| | Middle Aged | 20 | 2026 | 35342 | 0.190 |
Why?
| | Young Adult | 12 | 2022 | 13972 | 0.190 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 246 | 0.190 |
Why?
| | Glaucoma, Open-Angle | 1 | 2024 | 105 | 0.190 |
Why?
| | Proteins | 2 | 2022 | 1022 | 0.190 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 7 | 0.180 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 20 | 0.180 |
Why?
| | Immunoglobulin E | 2 | 2014 | 323 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2024 | 418 | 0.180 |
Why?
| | Emigration and Immigration | 3 | 2013 | 61 | 0.180 |
Why?
| | Demography | 5 | 2018 | 297 | 0.180 |
Why?
| | Myocardial Ischemia | 1 | 2023 | 279 | 0.180 |
Why?
| | Jews | 1 | 2021 | 24 | 0.180 |
Why?
| | Collagen Type VII | 1 | 2021 | 28 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2025 | 278 | 0.170 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 32 | 0.170 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 42 | 0.170 |
Why?
| | History, Medieval | 3 | 2021 | 46 | 0.170 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 38 | 0.170 |
Why?
| | Electrocardiography | 1 | 2024 | 630 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 781 | 0.170 |
Why?
| | Drug Implants | 1 | 2021 | 83 | 0.170 |
Why?
| | Adult | 20 | 2025 | 40013 | 0.170 |
Why?
| | Indians, Central American | 1 | 2020 | 6 | 0.170 |
Why?
| | Eosinophilia | 1 | 2023 | 225 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 532 | 0.160 |
Why?
| | Latin America | 2 | 2018 | 89 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 704 | 0.160 |
Why?
| | CpG Islands | 3 | 2025 | 166 | 0.160 |
Why?
| | Population Health | 1 | 2021 | 45 | 0.160 |
Why?
| | Reference Standards | 1 | 2020 | 181 | 0.160 |
Why?
| | Adolescent | 18 | 2021 | 22481 | 0.160 |
Why?
| | Adaptation, Biological | 1 | 2020 | 53 | 0.160 |
Why?
| | Pre-Eclampsia | 1 | 2022 | 204 | 0.150 |
Why?
| | Self Report | 2 | 2021 | 877 | 0.150 |
Why?
| | Principal Component Analysis | 2 | 2026 | 198 | 0.150 |
Why?
| | Lipase | 1 | 2020 | 74 | 0.150 |
Why?
| | Human Genetics | 1 | 2019 | 3 | 0.150 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 377 | 0.150 |
Why?
| | Gene Expression Regulation | 2 | 2025 | 2621 | 0.150 |
Why?
| | Apolipoprotein L1 | 1 | 2018 | 13 | 0.150 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 361 | 0.150 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 763 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1130 | 0.150 |
Why?
| | United States | 16 | 2025 | 15553 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 27 | 0.150 |
Why?
| | Antiporters | 1 | 2018 | 22 | 0.140 |
Why?
| | Europe | 5 | 2020 | 410 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2023 | 722 | 0.140 |
Why?
| | Liver Diseases | 1 | 2021 | 304 | 0.140 |
Why?
| | Primates | 1 | 2019 | 133 | 0.140 |
Why?
| | HLA-C Antigens | 1 | 2018 | 38 | 0.140 |
Why?
| | Chromosomes, Human, Y | 2 | 2008 | 36 | 0.140 |
Why?
| | Collagen Diseases | 1 | 2017 | 8 | 0.140 |
Why?
| | Fibrillar Collagens | 1 | 2017 | 14 | 0.140 |
Why?
| | Dermatitis, Atopic | 1 | 2021 | 333 | 0.130 |
Why?
| | Microbiota | 2 | 2023 | 759 | 0.130 |
Why?
| | Databases, Genetic | 3 | 2026 | 248 | 0.130 |
Why?
| | Epistasis, Genetic | 1 | 2017 | 67 | 0.130 |
Why?
| | Apolipoprotein A-V | 1 | 2017 | 3 | 0.130 |
Why?
| | Weight Gain | 1 | 2021 | 550 | 0.130 |
Why?
| | Gene Pool | 2 | 2013 | 4 | 0.130 |
Why?
| | History, Ancient | 3 | 2013 | 55 | 0.130 |
Why?
| | Saliva | 2 | 2020 | 247 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 312 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1507 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 266 | 0.130 |
Why?
| | Inflammation | 2 | 2025 | 2881 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2021 | 1051 | 0.130 |
Why?
| | Homozygote | 3 | 2023 | 201 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 884 | 0.120 |
Why?
| | Language | 2 | 2011 | 323 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1123 | 0.120 |
Why?
| | Colombia | 3 | 2021 | 42 | 0.120 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5743 | 0.110 |
Why?
| | Social Class | 2 | 2013 | 273 | 0.110 |
Why?
| | Genealogy and Heraldry | 1 | 2013 | 5 | 0.100 |
Why?
| | Africa, Southern | 3 | 2018 | 6 | 0.100 |
Why?
| | Minority Health | 1 | 2013 | 17 | 0.100 |
Why?
| | Health Surveys | 1 | 2016 | 512 | 0.100 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 25 | 0.100 |
Why?
| | Premature Birth | 1 | 2018 | 375 | 0.100 |
Why?
| | Urban Health | 1 | 2013 | 95 | 0.100 |
Why?
| | Population Dynamics | 2 | 2012 | 156 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1668 | 0.100 |
Why?
| | Search Engine | 1 | 2013 | 12 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1171 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 75 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 154 | 0.100 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 41 | 0.100 |
Why?
| | Neanderthals | 1 | 2013 | 13 | 0.100 |
Why?
| | Child | 15 | 2020 | 22725 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2013 | 485 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2012 | 27 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 464 | 0.100 |
Why?
| | Kallikreins | 1 | 2012 | 26 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2017 | 752 | 0.100 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 59 | 0.100 |
Why?
| | Mutation | 5 | 2018 | 4053 | 0.090 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 196 | 0.090 |
Why?
| | Air Pollution | 1 | 2016 | 330 | 0.090 |
Why?
| | Biological Evolution | 2 | 2019 | 493 | 0.090 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 560 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 166 | 0.090 |
Why?
| | HLA-B Antigens | 2 | 2022 | 57 | 0.090 |
Why?
| | History, 17th Century | 1 | 2011 | 14 | 0.090 |
Why?
| | History, 15th Century | 1 | 2011 | 10 | 0.090 |
Why?
| | History, 18th Century | 1 | 2011 | 16 | 0.090 |
Why?
| | Polynesia | 2 | 2021 | 3 | 0.090 |
Why?
| | Tuberculosis | 1 | 2014 | 290 | 0.090 |
Why?
| | Anthropometry | 2 | 2025 | 208 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 61 | 0.090 |
Why?
| | Cluster Analysis | 3 | 2023 | 526 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 332 | 0.080 |
Why?
| | Lung | 2 | 2016 | 4101 | 0.080 |
Why?
| | Chile | 2 | 2021 | 25 | 0.080 |
Why?
| | Respiratory Sounds | 1 | 2011 | 109 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2014 | 2318 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 147 | 0.080 |
Why?
| | Body Height | 2 | 2023 | 208 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 273 | 0.080 |
Why?
| | History, 21st Century | 1 | 2011 | 220 | 0.080 |
Why?
| | South Africa | 3 | 2015 | 208 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 327 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2020 | 72 | 0.080 |
Why?
| | Machine Learning | 2 | 2025 | 574 | 0.080 |
Why?
| | Peru | 2 | 2022 | 61 | 0.080 |
Why?
| | Vital Capacity | 1 | 2010 | 311 | 0.080 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2019 | 34 | 0.070 |
Why?
| | Electronic Health Records | 3 | 2021 | 1163 | 0.070 |
Why?
| | Africa | 3 | 2017 | 114 | 0.070 |
Why?
| | South America | 2 | 2020 | 56 | 0.070 |
Why?
| | Americas | 2 | 2018 | 26 | 0.070 |
Why?
| | Life Style | 2 | 2022 | 483 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1487 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1051 | 0.070 |
Why?
| | Signal Transduction | 2 | 2019 | 5214 | 0.070 |
Why?
| | Risk | 3 | 2018 | 906 | 0.070 |
Why?
| | Ants | 1 | 2007 | 27 | 0.070 |
Why?
| | Linguistics | 1 | 2007 | 27 | 0.070 |
Why?
| | Odds Ratio | 3 | 2014 | 1060 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2024 | 426 | 0.070 |
Why?
| | Whole Genome Sequencing | 2 | 2018 | 180 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2019 | 55 | 0.060 |
Why?
| | Speech | 1 | 2007 | 75 | 0.060 |
Why?
| | Human Genome Project | 2 | 2017 | 15 | 0.060 |
Why?
| | Graves Disease | 1 | 2026 | 44 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 39 | 0.060 |
Why?
| | Mendelian Randomization Analysis | 1 | 2025 | 54 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2025 | 10 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 787 | 0.060 |
Why?
| | Bias | 2 | 2019 | 208 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2025 | 46 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3832 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 549 | 0.060 |
Why?
| | Base Sequence | 3 | 2016 | 2199 | 0.060 |
Why?
| | Body Size | 1 | 2025 | 94 | 0.060 |
Why?
| | RNA | 1 | 2011 | 933 | 0.050 |
Why?
| | Phenethylamines | 1 | 2024 | 19 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 165 | 0.050 |
Why?
| | Torsades de Pointes | 1 | 2024 | 22 | 0.050 |
Why?
| | Argentina | 2 | 2015 | 29 | 0.050 |
Why?
| | Child, Preschool | 6 | 2020 | 11737 | 0.050 |
Why?
| | Microsatellite Repeats | 3 | 2011 | 160 | 0.050 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 626 | 0.050 |
Why?
| | Cohort Studies | 4 | 2019 | 5891 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 603 | 0.050 |
Why?
| | Prevalence | 2 | 2025 | 2830 | 0.050 |
Why?
| | Iran | 1 | 2023 | 45 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 75 | 0.050 |
Why?
| | Geography | 2 | 2016 | 202 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 589 | 0.050 |
Why?
| | Biology | 1 | 2024 | 92 | 0.050 |
Why?
| | Caribbean Region | 2 | 2013 | 29 | 0.050 |
Why?
| | Lipoprotein(a) | 1 | 2023 | 68 | 0.050 |
Why?
| | Minisatellite Repeats | 1 | 2002 | 39 | 0.050 |
Why?
| | Factor X | 1 | 2022 | 27 | 0.050 |
Why?
| | Factor VII | 1 | 2022 | 26 | 0.050 |
Why?
| | Genes | 1 | 2002 | 229 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 319 | 0.050 |
Why?
| | Blood Coagulation Factors | 1 | 2022 | 54 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3328 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 115 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2021 | 45 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 56 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2021 | 46 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 160 | 0.040 |
Why?
| | Bronchi | 2 | 2014 | 267 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 471 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2020 | 6366 | 0.040 |
Why?
| | Genome, Viral | 1 | 2022 | 224 | 0.040 |
Why?
| | Central America | 1 | 2020 | 24 | 0.040 |
Why?
| | China | 1 | 2021 | 226 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 686 | 0.040 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2020 | 20 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 247 | 0.040 |
Why?
| | Sulfonamides | 1 | 2024 | 582 | 0.040 |
Why?
| | Acyltransferases | 1 | 2020 | 81 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 769 | 0.040 |
Why?
| | Infant | 3 | 2021 | 9981 | 0.040 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.040 |
Why?
| | Topography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| | Asia, Northern | 1 | 2018 | 1 | 0.040 |
Why?
| | Mongolia | 1 | 2018 | 7 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1984 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 3006 | 0.040 |
Why?
| | Classification | 1 | 2019 | 43 | 0.040 |
Why?
| | Animals | 6 | 2024 | 38010 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2018 | 40 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 60 | 0.040 |
Why?
| | Receptors, Natural Killer Cell | 1 | 2018 | 16 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8072 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 151 | 0.030 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 481 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 77 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 576 | 0.030 |
Why?
| | New York City | 1 | 2017 | 90 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 921 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3380 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1095 | 0.030 |
Why?
| | DNA | 1 | 2024 | 1457 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 117 | 0.030 |
Why?
| | Multigene Family | 1 | 2017 | 205 | 0.030 |
Why?
| | DNA, Intergenic | 1 | 2016 | 29 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 2942 | 0.030 |
Why?
| | Musculoskeletal Diseases | 1 | 2017 | 87 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 64 | 0.030 |
Why?
| | Parents | 1 | 2025 | 1456 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1838 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2542 | 0.030 |
Why?
| | Prospective Studies | 3 | 2014 | 7899 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3577 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2019 | 376 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 670 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 307 | 0.030 |
Why?
| | Sexism | 1 | 2016 | 70 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 942 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 156 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 474 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 770 | 0.030 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2014 | 16 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 22 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2165 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2014 | 135 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 59 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 88 | 0.030 |
Why?
| | HapMap Project | 1 | 2013 | 4 | 0.030 |
Why?
| | Biomarkers | 1 | 2025 | 4241 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 650 | 0.030 |
Why?
| | Africa, Northern | 1 | 2013 | 4 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1622 | 0.030 |
Why?
| | Mammography | 1 | 2014 | 161 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2092 | 0.020 |
Why?
| | Blood Glucose | 1 | 2023 | 2316 | 0.020 |
Why?
| | Databases, Factual | 1 | 2019 | 1465 | 0.020 |
Why?
| | Skin Tests | 1 | 2013 | 96 | 0.020 |
Why?
| | Interleukin-13 | 1 | 2014 | 149 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 518 | 0.020 |
Why?
| | Th2 Cells | 1 | 2014 | 180 | 0.020 |
Why?
| | Hawaii | 1 | 2012 | 41 | 0.020 |
Why?
| | HLA Antigens | 1 | 2014 | 232 | 0.020 |
Why?
| | Genome, Mitochondrial | 1 | 2012 | 29 | 0.020 |
Why?
| | Income | 1 | 2013 | 198 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2261 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 60 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 169 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 425 | 0.020 |
Why?
| | Markov Chains | 1 | 2012 | 126 | 0.020 |
Why?
| | Boston | 1 | 2011 | 92 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 404 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 464 | 0.020 |
Why?
| | Angola | 1 | 2011 | 1 | 0.020 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 23 | 0.020 |
Why?
| | Mozambique | 1 | 2011 | 7 | 0.020 |
Why?
| | Canada | 1 | 2012 | 433 | 0.020 |
Why?
| | Air Pollutants | 1 | 2016 | 442 | 0.020 |
Why?
| | Insurance, Health | 1 | 2013 | 299 | 0.020 |
Why?
| | Africa South of the Sahara | 1 | 2011 | 47 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | North America | 1 | 2011 | 308 | 0.020 |
Why?
| | Culture | 1 | 2011 | 130 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 298 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 434 | 0.020 |
Why?
| | Allergens | 1 | 2013 | 408 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2011 | 199 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7031 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7153 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 811 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 59 | 0.020 |
Why?
| | Family | 1 | 2013 | 683 | 0.020 |
Why?
| | Social Behavior | 1 | 2011 | 291 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2107 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2011 | 258 | 0.020 |
Why?
| | Inbreeding | 1 | 2007 | 20 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 858 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1282 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1524 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1754 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3611 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 590 | 0.020 |
Why?
| | Reproduction | 1 | 2007 | 206 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1831 | 0.010 |
Why?
| | Smoking | 1 | 2012 | 1580 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2936 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2002 | 29 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2002 | 40 | 0.010 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2002 | 38 | 0.010 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2002 | 46 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 325 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6025 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18378 | 0.010 |
Why?
|
|
Gignoux's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|